[Further improving the standard of treatment for chronic myeloid leukemia].
Pu
Quan
Q
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use; D001374:Azacitidine / Q000627:therapeutic use; D001549:Benzamides; D019496:Cancer Vaccines / Q000627:therapeutic use; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010087:Oxides / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001152:Arsenicals; D001549:Benzamides; D019496:Cancer Vaccines; D010087:Oxides; D010879:Piperazines; D011743:Pyrimidines; D014409:Tumor Necrosis Factor-alpha; D000068877:Imatinib Mesylate; D001374:Azacitidine; D000077237:Arsenic Trioxide